AR099080A1 - FC REGION VARIATIONS WITH FCRN UNION PROPERTIES (FC NEONATAL RECEIVER) MODIFIED AND PROTEIN UNION TO MAINTAINED - Google Patents

FC REGION VARIATIONS WITH FCRN UNION PROPERTIES (FC NEONATAL RECEIVER) MODIFIED AND PROTEIN UNION TO MAINTAINED

Info

Publication number
AR099080A1
AR099080A1 ARP150100076A ARP150100076A AR099080A1 AR 099080 A1 AR099080 A1 AR 099080A1 AR P150100076 A ARP150100076 A AR P150100076A AR P150100076 A ARP150100076 A AR P150100076A AR 099080 A1 AR099080 A1 AR 099080A1
Authority
AR
Argentina
Prior art keywords
union
fcrn
neonatal
receiver
maintained
Prior art date
Application number
ARP150100076A
Other languages
Spanish (es)
Inventor
Schlothauer Tilman
SKOLAUT Alexander
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR099080A1 publication Critical patent/AR099080A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En el presente documento se comunica un polipéptido que comprende un primer polipéptido y un segundo polipéptido que comprende en dirección de N-terminal a C-terminal al menos una porción de una región bisagra de inmunoglobulina, que comprende uno o más restos de cisteína, un dominio CH2 de inmunoglobulina y un dominio CH3 de inmunoglobulina, en el que i) el primer polipéptido comprende las mutaciones I253A, H310A y H435A y el segundo polipéptido comprende las mutaciones H310A, H433A y Y436A, o ii) el primer polipéptido comprende las mutaciones I253A, H310A y H435A y el segundo polipéptido comprende las mutaciones L251D, L314D y L432D, o iii) el primer polipéptido comprende las mutaciones I253A, H310A y H435A y el segundo polipéptido comprende las mutaciones L251S, L314S y L432S. Formulación farmacéutica; uso.A polypeptide comprising a first polypeptide and a second polypeptide comprising at least a portion of an immunoglobulin hinge region, comprising one or more cysteine residues, a immunoglobulin CH2 domain and an immunoglobulin CH3 domain, in which i) the first polypeptide comprises mutations I253A, H310A and H435A and the second polypeptide comprises mutations H310A, H433A and Y436A, or ii) the first polypeptide comprises mutations I253A , H310A and H435A and the second polypeptide comprises mutations L251D, L314D and L432D, or iii) the first polypeptide comprises mutations I253A, H310A and H435A and the second polypeptide comprises mutations L251S, L314S and L432S. Pharmaceutical formulation; use.

ARP150100076A 2014-01-15 2015-01-13 FC REGION VARIATIONS WITH FCRN UNION PROPERTIES (FC NEONATAL RECEIVER) MODIFIED AND PROTEIN UNION TO MAINTAINED AR099080A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14151320 2014-01-15

Publications (1)

Publication Number Publication Date
AR099080A1 true AR099080A1 (en) 2016-06-29

Family

ID=49918650

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100076A AR099080A1 (en) 2014-01-15 2015-01-13 FC REGION VARIATIONS WITH FCRN UNION PROPERTIES (FC NEONATAL RECEIVER) MODIFIED AND PROTEIN UNION TO MAINTAINED

Country Status (1)

Country Link
AR (1) AR099080A1 (en)

Similar Documents

Publication Publication Date Title
MX2016008539A (en) Fc-region variants with modified fcrn- and maintained protein a-binding properties.
MX2016008540A (en) Fc-region variants with modified fcrn-binding properties.
CL2018000269A1 (en) Antibody constructs for flt3 and cd3
MX2016008782A (en) Fc-region variants with improved protein a-binding.
ECSP17073650A (en) FUSION PROTEINS
MX2020010061A (en) Fc-region variants with modified fcrn-binding and methods of use.
PE20170503A1 (en) INTERLEUKIN 2 / INTERLEUKIN-2 ALPHA RECEPTOR FUSION PROTEINS AND METHODS OF USE
CL2018000270A1 (en) Antibody constructs for cd70 and cd3.
CL2019001000A1 (en) Heterodimeric fc fusion proteins il15 / il15ralpha
EP3733716A4 (en) Fusion protein dimer using antibody fc region as backbone and use thereof
BR112019014986A2 (en) antibody targeting bcma and use of it
PE20211272A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
CL2016000232A1 (en) Stabilization of polypeptides containing crystallizable fragments
BR112018015670A2 (en) Bispecific t-cell antibody constructs
CL2017001070A1 (en) Variants of interferon a2b
EA201591700A1 (en) HYBRID PROTEINS APELINA AND THEIR APPLICATION
BR112019023071A2 (en) type ii tgf-beta receptor fusion proteins and use thereof
CO2018013104A2 (en) Cd40l-fc fusion polypeptides and their methods of use
BR112019008351A2 (en) immunoglobulins and their uses
UA117493C2 (en) HYBRID CONSTRUCTION INCLUDING AN ANTIGEN-SPECIFIC FRAGMENT SPECIFIC TO SERUM ALBUMIN AND AN EFFECTIVE COMPONENT AND METHODS
AR099080A1 (en) FC REGION VARIATIONS WITH FCRN UNION PROPERTIES (FC NEONATAL RECEIVER) MODIFIED AND PROTEIN UNION TO MAINTAINED
CR20150477A (en) IL-22 POLYPEPTIDES AND IL-22 FC FUSION PROTEINS AND METHODS OF USE
AR106146A1 (en) ANTI-TIGIT ANTIBODIES AND METHODS OF USE
AR090915A1 (en) PROTEIN OF FUSION OF PROTEIN LINFOPOYETINA ESTROMAL TIMICA CANINA WITH THE REGION FC OF IGG
AR095528A1 (en) INTERLEUCIN-22 (IL-22) POLYPEPTIDES AND IL-22 FUSION PROTEINS WITH HEAVY CHAIN FRAGMENT FC (IL-22 FC) AND METHODS OF USE